Diabetes

Expertise to speed trials, insights to drive value.

With broadening populations, expanding treatment options, and new digital support tools, understanding the science and the value in treating diabetes is becoming even more critical.

End-to-end support for diabetes

IQVIA brings together exceptional expertise in the diabetes market across the product lifecycle to help you increase the efficiency of your development program and maximize the value of new therapies.

  • Power your development program with real world data and predictive analytics to increase trial efficiency and bring differentiated diabetes therapies to patients, faster
  • Support your clinical and sales teams with an unparalleled source of diabetes enriched EMR and longitudinal prescription data
  • Couple real-world data with our Core Diabetes Model, the most widely used economic model in the healthcare industry, to accurately predict health outcomes and costs in type 1 and type 2 diabetes
  • Improve commercial outcomes by using real-world data to influence sales force effectiveness, targeting, call activity and brand performance

Case Study: Achieving ambitious goals in diabetes trials

In a recent Phase III Type I diabetes trial, IQVIA faced aggressive timelines to meet a submission deadline.

Through the power of the IQVIA Connected Intelligence™, we were able to accelerate both site ID and patient recruitment1 to help our customer meet the critical regulatory filing dates.

 

Comparison based on previous studies conducted by IQVIA in the same indication and geographies.

Leading the Way in Continuous Glucose Monitoring

HbA1c measures alone are no longer enough in diabetes drug development. Continuous Glucose Monitoring (CGM) is increasingly becoming a part of clinical research as well as routine patient management, as it helps improve medication compliance and enforce lifestyle interventions and overall protocol adherence.

IQVIA’s CGM solution has been recognized as a valid research tool. It is one of the few CGM solutions that are compliant with 21 CFR Part 11. By integrating devices with our automated data capture and advanced analytics, we’re able to deliver more robust data, with less delay – so you can reach better decisions, faster.

Solutions you may be interested in

Contact Us